Lotus and ERG Partner with CHDR to Bring NeuroKit® CNS Testing to the U.S35 Years of CNS Pharmacodynamic Testing Packed in a Portable Unit
Developed by CHDR, NeuroKit® is a mobile, “plug-and-play” adaptation of CHDR’s flagship NeuroCart® platform, which has set the gold standard in CNS pharmacodynamic testing for decades. With NeuroKit®, CHDR has translated this scientific rigor and data quality into a compact and scalable format that makes validated CNS assessments accessible to external research sites around the globe. This launch represents the culmination of close collaboration among CHDR, Lotus, and ERG. Through this initial exclusive partnership, NeuroKit® is being piloted at Clinical Pharmacology of Miami (CPMI), ERG’s state-of-the-art Phase 1 unit, with strong support from both the ERG and Lotus Clinical Research teams. This collaboration marks the first deployment of NeuroKit® in the United States. NeuroKit® is in the final stages of clinical trial validation, ensuring the highest standards of data quality and operational excellence, with services expected to be available to clients in late 2025. “We’re thrilled to bring this innovation into our U.S. research infrastructure,” said William Martin, President of Lotus. “The NeuroKit® allows Lotus to deliver high-fidelity, early-phase CNS testing within ERG’s extensive site network. With NeuroKit added to our portfolio of services and capabilities, we can provide Sponsors the ability to gain critical early insights, accelerate development, and reduce risk.” “This milestone aligns with our mission to make CNS pharmacodynamic testing more accessible across regions,” said Geert Jan Groeneveld, CEO of CHDR. “We’re proud to collaborate with ERG and Lotus as we bring NeuroKit® to life in a high-quality U.S. setting.” Clinical teams from ERG and Lotus are completing comprehensive training with CHDR to ensure harmonized implementation and data fidelity to CHDR. The integration of NeuroKit® at CPMI represents a major advancement in scalable, distributed CNS research. Neurokit® collaboration was introduced during the 2025 American Society of Clinical Psychopharmacology (ASCP) annual meeting in Phoenix in June. Watch the NeuroKit® in action: Watch Video About CHDR About Evolution Research Group (ERG) About Lotus Clinical Research, LLC |
Lotus Clinical Research, Evolution Research Group (ERG), and the Centre for Human Drug Research (CHDR) are proud to announce the U.S. launch of NeuroKit®, CHDR’s groundbreaking portable CNS testing platform.